There is still time to register patients onto EAQ202 for the chance to win a prize! The prize will be awarded to the Coach and MVP Player with the most accruals to EAQ202 during the tournament.

As of March 25, Bon Secours St. Francis is in the lead with 6 accruals and Spartanburg is not far behind with 5 accruals.

ECOG–ACRIN TMIST Update

ECOG–ACRIN announced accruals more than half way to target for TMIST. Significantly, Black participation has risen above 20%! Recruitment of diverse populations ensures that results will be applicable to all.

Spartanburg has enrolled more than 1,300
participants onto this study and, in the month of March, has averaged 8 enrollments a week. Way to go, Lynde and Team!

To read the full press release to learn more about their efforts to increase minority participation follow the link below.

Full Press Release

Newly Activated Studies

These studies have recently activated. More information can be found on CTSU.

- **S1800D**: A Phase II/III Study of N-803 (ALT-803) Plus Pembroliizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti–PD–1 or Anti–PD–L1 Therapy (Lung–MAP Non-Match Sub-Study)
- **A211801**: BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation
- **NRG–GI008**: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE–US)
- **A032001**: MAIN–CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
- **URCC–21038 (DiRECT)**: Disparities in Results of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti–PD–1/anti–PD–L1 Immunotherapy in a Community Oncology Setting
- **AOST2031**: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Research Base Meetings

- **SWOG**: April 6–9, 2022  
  Virtual/In-Person  
  Registration Now Open!
- **ECOG–ACRIN**: May 4–6, 2022  
  Chicago, IL / Virtual
Registration Now Open!

Alliance: May 11–14, 2022
Virtual/In-Person

Registration Now Open!

The Cancer Letter

March 25, 2022

March 18, 2022

March 11, 2022

March 4, 2022

February 25, 2022

February 18, 2022
GY3 February 2022 Accruals By Affiliate Site

NCI Assigned Performance Tracking
GY3 February YTD 2022
## Underrepresented Populations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AYA (15-39 yrs.)</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>6</td>
<td>3</td>
<td>2</td>
<td>4%</td>
<td>15.04%</td>
</tr>
<tr>
<td>Older Adults (&gt;65 yrs.)</td>
<td>24</td>
<td>16</td>
<td>13</td>
<td>22</td>
<td>13</td>
<td>10</td>
<td>12</td>
<td>55%</td>
<td>33%</td>
</tr>
<tr>
<td>African American</td>
<td>12</td>
<td>15</td>
<td>12</td>
<td>7</td>
<td>7</td>
<td>5</td>
<td>10</td>
<td>17.6%</td>
<td>21%</td>
</tr>
<tr>
<td>Other Minorities</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0.4%</td>
<td>1.2%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>1%</td>
<td>2.1%</td>
</tr>
<tr>
<td>Rural</td>
<td>23</td>
<td>26</td>
<td>19</td>
<td>11</td>
<td>9</td>
<td>7</td>
<td>12</td>
<td>35%</td>
<td>33%</td>
</tr>
</tbody>
</table>

## CCDR Corner

**CCDR Registrations GY3 (Aug - Feb. 2022) = 28**

- **URCC-18110CD, ENABLE (Patient):** 4
- **URCC-18110CD, ENABLE (Caregiver):** 2
- **URCC-18110CD, Tenhealth:** 2
- **WF-30917CD:** 2
- **WF-1805CD:** 5
- **WF-1805CD (NON-PATIENT):** 0
- **URCC-18004CD (Drug Shortage Participation):** X
- **URCC-18110CD (NON-PATIENT):** 0
- **URCC-18110CD (PATIENT):** 4
- **URCC-18110CD (CAREGIVER):** 2
- **SWOG S19112CD (PATIENT):** 1
- **SWOG S19112CD (CAREGIVER):** 1

<table>
<thead>
<tr>
<th>Protocol</th>
<th>SMC</th>
<th>BSSF</th>
<th>AnMed</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG-CC007CD</td>
<td>0</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>WF-30917CD</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>WF-1805CD</td>
<td>5</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>WF-1805CD (NON-PATIENT)</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>URCC-18004CD</td>
<td>X</td>
<td>X</td>
<td>N/A</td>
</tr>
<tr>
<td>URCC-18110CD (NON-PATIENT)</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>URCC-18110CD (PATIENT)</td>
<td>4</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>URCC-18110CD (CAREGIVER)</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>SWOG S19112CD (PATIENT)</td>
<td>1</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>SWOG S19112CD (CAREGIVER)</td>
<td>1</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Site Total</td>
<td>15</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>UC-NCORP Total</td>
<td>28</td>
<td>Drug Shortage Participation</td>
<td></td>
</tr>
</tbody>
</table>

## All About AYA
Diving into Disparities

Alliance Disparities Enrollment Report

An important aim of the Alliance is to identify and eliminate disparities in cancer incidence, morbidity, and mortality. New strategies will include monitoring the accruals of underserved and minority populations to Alliance studies and helping the Alliance investigators reach certain goals. With the new online report – the Alliance Disparities Enrollment Report – institutions can now track accruals to all Alliance studies (overall and by specific study) on a weekly basis by race/ethnicity, rural versus urban, age and gender.

For more information and to access the dashboard, visit the Alliance website with your CTEP IAM log in
QA with Kelsey

Upcoming Audits

URCC: March 28 – April 1, 2022

ECOG-ACRIN: April 26 – 28, 2022

Do you have any staff you would like highlighted in The Connector?
Please submit it by the 15th of the month to Alaina: a kennedy@srhs.com

Connect with us on LinkedIn! @UpstateCarolinaNCORP

Click here to visit our website

Administrator
Kamara Mertz-Rivera, MA, CCRC
Email: UpstateNCORP@srhs.com
Phone: 864-560-6104

Regulatory
Laura Bailey, BS, CCRP
Email: UpstateNCORPRegulatory@srhs.com
Phone: 864-560-6954

Finance
Alex Akkary, MBA
Email: UpstateNCORPFinance@srhs.com
Phone: 864-560-6967

Quality Assurance
Kelsey Bridges, MSHS, ACRP-CP
Email: UpstateCORPQA@srhs.com
Phone: 864-560-1961

CCDR Lead
Melyssa Foust, MSN, RN, OCN
Email: UpstateCORPCCDR@srhs.com
Phone: 864-560-1035

AYA Coordinator
Heather Schwartz, MPH, HTL
Email: heather_schwartz@bshsi.org
Phone: 864-603-6212